Back To Search Results

GABA Inhibitors

Editor: Nazia M. Sadiq Updated: 7/30/2023 1:06:39 PM


Gamma-aminobutyric acid (GABA) inhibitors, or GABA antagonists, are drugs that inhibit the action of GABA, the primary inhibitory neurotransmitter of the central nervous system. They predominantly work at the GABA receptor. GABA receptors categorize into the GABA-A receptor and GABA-B receptor subtypes.[1] A GABA-C receptor also exists, but it is typically classified as a subtype of GABA-A receptors and named GABA-A-rho.[2]

While GABA-A receptors are ionotropic receptors that gate chloride channels, GABA-B receptors are metabotropic G-protein coupled receptors. The receptor subtypes can also be differentiated based on their selectivity to agonists and antagonists: GABA-A receptors are antagonized by bicuculline and insensitive to baclofen, whereas GABA-B receptors are agonized by baclofen and insensitive to bicuculline. The potency of most GABA-A receptor antagonists is mostly independent of receptor subunit composition, in contrast to GABA-A receptor agonists.[3]

Examples of GABA-A receptor antagonists include flumazenil, bicuculline, picrotoxin/picrotoxinin, gabazine, suramin, sepranolone, salicylidene salicylhydrazide (SCS), bilobalide, RU5135, and 4-(3-biphenyl-5-(4-piperidyl)-3-isoxazole (3-biphenyl-4-PIOL).[3] Examples of GABA-C receptor antagonists include 1,2,5,6-tetrahydropyridin-4-methylphosphinic acid (TPMPA).[4]

Examples of GABA-B receptor antagonists include 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP).[4]

Issues of Concern

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Issues of Concern

Mechanism of Action

The mechanism of action of GABA receptor antagonists depends on the drug itself. Bicuculline is a competitive antagonist at GABA-A receptors; it binds to GABA-A receptors and thus inhibits the binding of GABA. Picrotoxinin, the active component of picrotoxin, acts as a non-competitive antagonist at GABA-A receptors, binding to GABA ionophores.[5]

Picrotoxin also acts on GABA-C receptors, glycine, and 5-HT3 receptors, binding in the pore region of these ligand-gated ion channels.[3] Gabazine acts as a competitive antagonist at GABA-A receptors.[6] Salicylidene salicylhydrazide (SCS) acts as an inhibitor of activating GABA-A receptors containing the beta-1 subunit.[7] RU5135, a steroid derivative, acts as a competitive antagonist with a common site of action as bicuculline but is much more potent than bicuculline. RU5135 also acts as a glycine antagonist.[8] 3-biphenyl-4-PIOL acts as a selective GABA-A receptor antagonist.[9] Suramin is a competitive antagonist selective to GABA-A receptors, specifically the alpha-1-beta-2-gamma-2 GABA-A receptor. Suramin is also a non-selective antagonist of purinergic receptors.[10]

Flumazenil acts as a specific benzodiazepine antagonist at GABA-A receptors. However, research has shown that flumazenil also has partial positive allosteric modulatory activity at GABA-A receptors containing the alpha-6 subunit.[11]

Some research suggests that the action of flumazenil can vary depending on the presence of other GABA-A receptor modulators. When given at low doses and in the presence of a benzodiazepine, flumazenil acts as a low-efficacy GABA-A receptor antagonist. On the other hand, when given at high doses or in the presence of a GABA-A agonist that acts at a site other than the benzodiazepine site, flumazenil acts as a low-efficacy GABA-A receptor partial agonist.[12]

Clinical Significance

GABA receptor antagonists produce convulsant and stimulant effects and are mainly used for research. For example, bicuculline and gabazine are frequently utilized to dissect GABA-A receptor components in neurons functionally. These GABA receptor antagonists act as subtype-selective compounds and help to study the behavioral effects of the different GABA-A receptor subtypes.[7]

However, not all GABA-A receptor antagonists are convulsants, such as the experimental drug bilobalide, derived from Ginkgo biloba. Bilobalide instead acts as an anticonvulsant and neuroprotectant by reducing the release of L-glutamate and reducing excitation, as well as inhibiting GABA synthesis via the inhibition of glutamate decarboxylase.[3]

Some GABA receptor antagonists, such as flumazenil, are used for the management of suspected benzodiazepine overdoses and the reversal of benzodiazepine sedative effects associated with general anesthesia. Flumazenil is a benzodiazepine GABA-A receptor antagonist, preventing benzodiazepines from binding to the benzodiazepine binding site on GABA-A receptors and preventing the influx of chloride ions and resulting hyperpolarization, thus preventing the GABA-ergic inhibitory effects.[13]

In this manner, flumazenil is the antidote when a benzodiazepine overdose is suspected or during procedures that use benzodiazepines as anesthetic agents. Flumazenil can also be useful in the treatment of benzodiazepine dependence and the management of benzodiazepine withdrawal syndrome. Flumazenil has been shown to alleviate persistent withdrawal symptoms, reduce benzodiazepine craving, and decrease post-detoxification relapse rates.[12]

There has been further research on the clinical indications of flumazenil, with one study finding that flumazenil may improve the features of Parkinson disease.[14] There is also some interest in using GABA receptor antagonists, such as flumazenil, for treating idiopathic hypersomnia, a rare disorder of hypersomnolence that can be distinguished from narcolepsy by the absence of rapid eye movement sleep disturbances. Given that GABA-A receptors regulate sleep and wakefulness, Rye et al proposed that an excess of GABA signaling may be responsible for idiopathic hypersomnia. Thus, flumazenil may be a viable option for treating the condition. They found flumazenil improved psychomotor vigilance and sleepiness in all patients roughly 2 hours after administration.[15]

Suramin is an anti-parasitic drug used to treat African human trypanosomiasis or sleeping sickness. However, research has shown that suramin may be used in the treatment of autism by normalizing the hyperactive response of the hypothalamus-pituitary-adrenal (HPA) axis by antagonizing GABA-A receptors.[10]

One study found that sepranolone, a GABA-A receptor-modulating steroid antagonist to the progesterone metabolite allopregnanolone, significantly reduced negative mood in women with premenstrual dysphoric disorder (PMDD).[16]

Nursing, Allied Health, and Interprofessional Team Interventions

Given the full range of clinical applications of GABA receptor antagonists, interprofessional communication and care coordination are essential when using these medications. For example, physicians, mid-level practitioners, nurses, pharmacists, and other health professionals must be knowledgeable about treating benzodiazepine overdoses with flumazenil. However, flumazenil’s effects are inconsistent, and not all patients may respond. Additionally, anesthesiologists carry a significant responsibility to be well-versed regarding the use of GABA receptor antagonists as they may be used to reverse the effects of anesthesia.

As research into different GABA receptor antagonists continues to expand their clinical utility, all health professionals must keep current on the research and clinical literature to provide patients with the highest quality of care. An interprofessional team that prioritizes communication, collaboration, and shared decision-making through an integrated, patient-centered approach can enhance outcomes and team performance, which leads to improved patient safety. Each interprofessional team member is responsible for identifying complications with the treatment of GABA receptor antagonists and responding appropriately and promptly to ensure the best possible patient prognosis and outcome.

Nursing, Allied Health, and Interprofessional Team Monitoring

In a healthcare setting, when a patient receives intravenous benzodiazepines, a nurse dedicated to monitoring the patient is essential. Also, resuscitative equipment, including flumazenil, must be available in the room before starting a procedure that utilizes these agents.



Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature. 1981 Mar 12:290(5802):149-52     [PubMed PMID: 6259535]

Level 3 (low-level) evidence


Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacological reviews. 2008 Sep:60(3):243-60. doi: 10.1124/pr.108.00505. Epub 2008 Sep 12     [PubMed PMID: 18790874]

Level 3 (low-level) evidence


Johnston GA. Advantages of an antagonist: bicuculline and other GABA antagonists. British journal of pharmacology. 2013 May:169(2):328-36. doi: 10.1111/bph.12127. Epub     [PubMed PMID: 23425285]

Level 3 (low-level) evidence


Chebib M, Johnston GA. The 'ABC' of GABA receptors: a brief review. Clinical and experimental pharmacology & physiology. 1999 Nov:26(11):937-40     [PubMed PMID: 10561820]

Level 3 (low-level) evidence


Andrews PR, Johnston GA. GABA agonists and antagonists. Biochemical pharmacology. 1979 Sep 15:28(18):2697-702     [PubMed PMID: 40560]

Level 3 (low-level) evidence


Heaulme M, Chambon JP, Leyris R, Molimard JC, Wermuth CG, Biziere K. Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site. Brain research. 1986 Oct 8:384(2):224-31     [PubMed PMID: 3022866]

Level 3 (low-level) evidence


Thompson SA, Wheat L, Brown NA, Wingrove PB, Pillai GV, Whiting PJ, Adkins C, Woodward CH, Smith AJ, Simpson PB, Collins I, Wafford KA. Salicylidene salicylhydrazide, a selective inhibitor of beta 1-containing GABAA receptors. British journal of pharmacology. 2004 May:142(1):97-106     [PubMed PMID: 15100159]

Level 3 (low-level) evidence


Simmonds MA, Turner JP. Antagonism of inhibitory amino acids by the steroid derivative RU5135. British journal of pharmacology. 1985 Mar:84(3):631-5     [PubMed PMID: 3986429]

Level 3 (low-level) evidence


Frølund B, Jensen LS, Storustovu SI, Stensbøl TB, Ebert B, Kehler J, Krogsgaard-Larsen P, Liljefors T. 4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships. Journal of medicinal chemistry. 2007 Apr 19:50(8):1988-92     [PubMed PMID: 17375905]

Level 3 (low-level) evidence


Luo H, Wood K, Shi FD, Gao F, Chang Y. Suramin is a novel competitive antagonist selective to α1β2γ2 GABA(A) over ρ1 GABA(C) receptors. Neuropharmacology. 2018 Oct:141():148-157. doi: 10.1016/j.neuropharm.2018.08.036. Epub 2018 Aug 30     [PubMed PMID: 30172846]


Hadingham KL, Garrett EM, Wafford KA, Bain C, Heavens RP, Sirinathsinghji DJ, Whiting PJ. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors. Molecular pharmacology. 1996 Feb:49(2):253-9     [PubMed PMID: 8632757]

Level 3 (low-level) evidence


Hulse G, Kelty E, Hood S, Norman A, Basso MR, Reece AS. Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System. Current pharmaceutical design. 2015:21(23):3325-42     [PubMed PMID: 26088116]


Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. British journal of clinical pharmacology. 2014 Feb:77(2):285-94. doi: 10.1111/bcp.12023. Epub     [PubMed PMID: 23126253]

Level 3 (low-level) evidence


Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2003 Jun:18(6):683-5     [PubMed PMID: 12784272]


Rye DB, Bliwise DL, Parker K, Trotti LM, Saini P, Fairley J, Freeman A, Garcia PS, Owens MJ, Ritchie JC, Jenkins A. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Science translational medicine. 2012 Nov 21:4(161):161ra151. doi: 10.1126/scitranslmed.3004685. Epub     [PubMed PMID: 23175709]


Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T. Treatment of premenstrual dysphoric disorder with the GABA(A) receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017 Jun:80():46-55. doi: 10.1016/j.psyneuen.2017.02.031. Epub 2017 Mar 1     [PubMed PMID: 28319848]

Level 1 (high-level) evidence